Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct 29:249:108464.
doi: 10.1016/j.rmed.2025.108464. Online ahead of print.

Discontinuation of supportive therapies in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor - A patient-reported outcomes' study

S Ahting  1 , M Vogel  2 , B Wollschläger  3 , C Henn  4 , C Ludwig  3 , U Issa  5 , A-L Strehlow  6 , M Vom Hove  7 , J Hentschel  8 , F Prenzel  7
Affiliations
Free article

Discontinuation of supportive therapies in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor - A patient-reported outcomes' study

S Ahting et al. Respir Med. .
Free article

Abstract

Background: With the introduction of elexacaftor/tezacaftor/ivacaftor (ETI), there has been significant impact on the health and quality of life of people with cystic fibrosis, raising questions about the need for ongoing supportive therapies. This study examines patient-reported outcomes related to ETI and its influence on supportive therapy adherence.

Methods: An anonymized cross-sectional survey was conducted among 1589 members of the German Cystic Fibrosis Association to assess treatment burden, and quality of life before and during ETI treatment, focusing on adherence and factors affecting the continuation of supportive therapies.

Results: Of the 406 respondents (effective response rate 25.5 %), 276 were receiving ETI. Analysis showed increased quality of life and decreased symptoms, with a majority reporting reduced or absent cough (93 %) and sputum (91 %) following ETI treatment. The desire to reduce therapy burden was high, with 80.4 % reporting a prior or present reduction of supportive therapies, particularly of mucoactive inhalations and antibiotics. Age was a significant factor in therapy adherence, with higher adherence in adolescents than adults. Improved quality of life and better lung function correlated with greater adherence to antibiotic inhalations, while better lung function increased the likelihood of reducing mucoactive therapies.

Conclusions: Many people with CF are reducing supportive therapies despite the absence of clear guidelines. Decision-making is influenced by factors such as the desire to lessen therapy burden, reduced symptom severity, and maximizing therapeutic effects. The study highlights the need for comprehensive recommendations and calls for further research to understand the factors involved in therapy adherence and reduction.

Keywords: Cystic fibrosis; Patient reported outcome measures; Therapeutic adherence.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: FP received personal fees from Sanofi Aventis, Allergopharma, Stallergenes Greer, Vertex Pharmaceuticals, Takeda Pharma, and ALK-Abelló outside of the submitted work. MvH received personal fees from Vertex Pharmaceuticals. BW received personal fees from Vertex Pharmaceuticals outside of the submitted work. All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

LinkOut - more resources